A Gene Therapy ‘First’: Huntington’s Disease Successfully Treated in Early Trial
In an hours-long brain surgery, doctors delivered a new piece of genetic code directly into patients’ brains. Early…
Opus Genetics to Present at Upcoming Medical and Industry Conferences in October 2025
Opus Genetics, Inc. RESEARCH TRIANGLE PARK, N.C., Oct. 02, 2025 (GLOBE NEWSWIRE) — Opus Genetics, Inc. (Nasdaq: IRD),…
Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5)
Opus Genetics, Inc. Pediatric participants demonstrated large gains in cone-mediated vision; therapy remains well tolerated with no ocular…
Opus Genetics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
Opus Genetics, Inc. RESEARCH TRIANGLE PARK, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) — Opus Genetics, Inc. (Nasdaq: IRD)…
Biologic Therapeutics Market to Hit $794.5 Billion by 2029
“Driven by Rising Chronic Disease Burden and Breakthrough FDA Approvals, Biopharmaceutical Market Surges with Demand for Monoclonal Antibodies,…
Sarepta Refused FDA’s Request to Halt Elevidys Shipments
(Bloomberg) — Sarepta Therapeutics Inc. has refused to pause all shipments of its Elevidys treatment after three deaths…
Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Opus Genetics, Inc. RESEARCH TRIANGLE PARK, N.C., July 03, 2025 (GLOBE NEWSWIRE) — Opus Genetics, Inc. (Nasdaq: IRD),…